Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00109-014-1165-y http://scihub22266oqcxt.onion/10.1007/s00109-014-1165-y C5696571!5696571!24852181     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mol+Med+(Berl) 2014 ; 92 (7): 697-707 Nephropedia Template TP {{tp|p=24852181|t=2014. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer |pdf=|usr=}}{{24852181}} gab.com Text Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer JO: J Mol Med (Berl) http://www.kidney.de/pget.php?&tw=1&pmid=24852181 #FOAvip In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. As the genomic classification of lung cancer continues to evolve and as the mechanisms of acquired resistance to targeted therapies become elucidated and more improved target-specific drugs come into sight, the future will see more promising results from the clinic through the development of new therapeutic strategies to overcome, or prevent the development of, resistance for lung cancer patients. Twit Text FOAVip Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer ????J Mol Med (Berl) http://www.kidney.de/pget.php?&tw=1&pmid=24852181 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24852181 #FOAvip English Wikipedia <ref>{{Cite pmid|24852181}}</ref> Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer #MMPMID24852181 Gower A; Wang Y; Giaccone G J Mol Med (Berl) 2014[Jul]; 92 (7): 697-707 PMID24852181show ga In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. As the genomic classification of lung cancer continues to evolve and as the mechanisms of acquired resistance to targeted therapies become elucidated and more improved target-specific drugs come into sight, the future will see more promising results from the clinic through the development of new therapeutic strategies to overcome, or prevent the development of, resistance for lung cancer patients. äOncogenic drivers, targeted therapies, and acquired resistance in non-(epmc).pdf DeepDyve Pubget Overpricing